Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Thyroid Gland Medullary Carcinoma
Interventions: Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan, Neck Dissection, Surveillance, Thyroid Lobectomy, Thyroidectomy, Ultrasound Imaging; Procedure · Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery; Drug · Procedure
Lead sponsor: Robert H. Lurie Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Pre-diabetes, Glucose Intolerance
Interventions: Dexcom G6 Continuous Glucose Monitor (CGM) System; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lakeland, Florida

Conditions: Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions: Estrace, Anastrozole; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania

Conditions: Hyperglycemia
Interventions: Freestyle Libre 3 Continuous Glucose Monitor; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 26 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado

Conditions: Breast Cancer
Interventions: Mobile phone app + patient navigation; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metastatic Breast Cancer
Interventions: Erdafitinib, Palbociclib, Fulvestrant; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • New York, New York • Pittsburgh, Pennsylvania + 3 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Type 1 Diabetes, Hashimoto Disease, Graves Disease, Addison Disease, Autoimmune Polyglandular Syndrome Type III, Depression, Endocrine System Diseases
Interventions: Telehealth Resource Oriented Music Therapy; Behavioral
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boone, North Carolina

Conditions: Breast Cancer
Interventions: oophorectomy, Tamoxifen; Procedure · Drug
Lead sponsor: International Breast Cancer Research Foundation; Other
Eligibility: 18 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Transplant, Diabetes
Interventions: Oral glucose tolerance test, IV Glucose Tolerance Test; Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
Interventions: Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy; Drug · Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 55
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more

Conditions: Chronic Conditions, Multiple
Interventions: No intervention being administered; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 21 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions: Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY; Combination Product · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more

Conditions: Alopecia
Interventions: Platelet Rich Plasma system; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Acromegaly
Interventions: Oral Glucose Tolerance Test (OGTT); Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Invasive Lobular Carcinoma (mILC)
Interventions: circulating tumor DNA (ctDNA); Diagnostic Test
Lead sponsor: Julia Foldi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anovulation, FHA, Eumenorrhea, Polycystic Ovary Syndrome
Interventions: Screening evaluation, Meal Response, Blood Collection, Functional MRI, Endocrine Assessment; Procedure · Genetic
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Physical Activity
Interventions: Mindfulness, Distraction, Self-monitoring; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years to 40 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Charlottesville, Virginia

Conditions: Breast Cancer, Residual
Interventions: chemotherapy or endocrine therapy for breast cancer; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2042
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Glucose Risk Assessment in Employer Populations

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Feasibility of CGM Use in Hospitalized Youth

Improving Adherence to EHT Among Breast Cancer Patients

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Fatigue, Sleep Disorders and Endocrine Abnormalities in TBI Patients

Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Perceptions of LARC Among AYA With Chronic Illness

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

Islet Cell Transplant for Type 1 Diabetes

FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity

Strategies to Enhance the Experience of Exercise

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer